Connect with us

BioPharma

Clean Vision Corp (OTCMKTS: CLNV) Running Northbound as Subsidiary Clean-Seas Pyrolysis Plastic Waste-to-Energy Gains Traction

Published

on

Clean Vision Corp (OTCMKTS: CLNV) is making a strong move northbound in recent trading on a significant surge of volume transforming into a volume leader in small caps. Currently under heavy accumulation CLNV is starting to get noticed by some big plays in small caps looking for a run like CLNV had back in 2020 when it ran to $0.45 per share. Recently CLNV achieved OTCQB fully reporting status which will bring broader visibility for the Company exposing it to new customers, investors, and strategic partners. 

It’s easy to get excited about CLNV making a move on the $125 billion hydrogen economy with its wholly owned subsidiary Clean-Seas who has built a solid foundation for its patent-pending Plastic Conversion Network (PCN). Clean-Seas’ pyrolysis plant for CSIR/IICT in Hyderabad will soon be operational, where it will demonstrate the Company’s scalable technology for converting waste plastic into valuable commodities such as low sulfur fuels and AquaH. CLNV management is also targeting one or more corporate acquisitions or strategic alliances in the clean tech sector that will increase and diversify its synergistic assets, markets, and revenue streams. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Clean Vision Corp (OTCMKTS: CLNV) operating out of Los Angeles, California acquires and operates a portfolio of synergistic companies in the sustainable clean technology and green energy sectors. Clean Vision portfolio companies are supported by consultancy services, connecting organizations to new verticals, accelerating time to market and profitability. Management worked hard behind the scenes in 2021 bring CLNV to fully reporting OTCQB.

The Company is led by CEO Daniel Bates, a serial entrepreneur with extensive start-up experience. 10+ years in the renewable energy sector. Also, on the boards of directors sits Michael K. Dorsey, Ph.D., M.A., M.F.S, a recognized expert on global energy, environment, finance and sustainability matters who served high level positions under three ex-presidents. 

Clean Vision’s subsidiary Clean-Seas, Inc. provides efficient and cost-effective technology solutions that address the global waste plastic crisis as well as creating economic opportunity and social benefit in emerging and developed economies across the world. Clean-Seas offers “best in class” pyrolysis technology deployment for plastic waste-to-energy recycling, including securing feedstock and off-take agreements.  

Clean Seas utilizes pyrolysis plants connected by a blockchain network to convert plastic waste into energy. Pyrolysis is defined as the thermal decomposition of lignocellulosic derivatives under inert condition in oxygen‐deficient environment. Pyrolysis has been getting further consideration as an effective technique for transforming biomass into bio‐oil throughout the modern eras. The eventual objective of pyrolysis is to yield high‐value energy products for contending with and gradually supplanting non‐renewable fossil fuels. The plastic to fuel market size to reach $8804.20 million by 2028. The pyrolysis segment led the global market with 65.7% market share in 20 

Clean-Seas has built a solid foundation for its patent-pending Plastic Conversion Network (PCN) with the signing of multiple preliminary agreements with government officials and private sector leaders in Latin America, Middle East and Africa. Those agreements include UAE, Cameroon, Somaliland, DRC, Ecuador, Malaysia, Georgia (Caucasus) as well as solid traction in Cape Cod, Massachusetts. The Company has also filed for trademark protection for its unique brand of clean hydrogen, AquaH™ — hydrogen derived from a plastic waste stream. 

To Find out the inside Scoop on CLNV Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CLNV

Clean-Seas has partnered with India’s prestigious Council for Scientific and Industrial Research (CSIR) and the Indian Institute of Chemical Technology (IICT) in order to further develop and commercialize its waste plastic-to-energy technologies and services. To accelerate this line of business, Clean-Seas has purchased and is delivering a pilot pyrolysis plant to Hyderabad for commissioning next month. 

Building upon its successes last year, 2022 will see Clean-Seas’ pyrolysis plant operational for CSIR/IICT in Hyderabad, where it will demonstrate the Company’s scalable technology for converting waste plastic into valuable commodities such as low sulfur fuels and AquaH. The Company last week announced it has secured an option to develop and exclusively license a proprietary hydrogen fuel cell technology from Kingsberry Power that will enable it to provide a complete end-to-end solution: energy from a waste stream converted and providing clean electricity to an end user. The pyrolysis and fuel cell technologies combined gives Clean-Seas a disruptive advantage as it enters the $125 billion hydrogen economy. 

While pyrolysis is a well-established technology worldwide, Clean-Seas expects to use its Hyderabad facility to demonstrate its suite of new technologies to officials from Asia, the Middle East and other nations entering the hydrogen economy. The facility will enable its nascent PCN to advance in India while it further penetrates new global markets. The Company is actively discussing new PCN opportunities stretching from the UAE — to the US where it intends to tap into billions of dollars in the new Administration’s funding for clean-tech infrastructure. 

https://twitter.com/CleanVisionCorp/status/1501203070180597762

 For more on CLNV Subscribe Right Now!

CLNV is making a strong move northbound in recent trading on a significant surge of volume transforming into a volume leader in small caps. Currently under heavy accumulation CLNV is starting to get noticed by some big plays in small caps looking for a run like CLNV had back in 2020 when it ran to $0.45 per share. Recently CLNV achieved OTCQB fully reporting status which will bring broader visibility for the Company exposing it to new customers, investors, and strategic partners.  It’s easy to get excited about CLNV making a move on the $125 billion hydrogen economy with its wholly owned subsidiary Clean-Seas who has built a solid foundation for its patent-pending Plastic Conversion Network (PCN). Clean-Seas’ pyrolysis plant for CSIR/IICT in Hyderabad will soon be operational, where it will demonstrate the Company’s scalable technology for converting waste plastic into valuable commodities such as low sulfur fuels and AquaH. CLNV management is also targeting one or more corporate acquisitions or strategic alliances in the clean tech sector that will increase and diversify its synergistic assets, markets, and revenue streams. We will be updating on CLNV when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CLNV.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CLNV  either long or short and we have not been compensated for this article

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

on

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

on

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.